United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - granisetron hydrochloride - solution for injection - 1mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

hameln pharma ltd - granisetron hydrochloride - solution for injection - 1mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - granisetron hydrochloride granisetron - solution for injection - 1 mg/ml

United States - English - NLM (National Library of Medicine)

heron therapeutics, inc. - granisetron (unii: wzg3j2mcol) (granisetron - unii:wzg3j2mcol) - granisetron 10 mg in 0.4 ml - sustol is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (mec) or anthracycline and cyclophosphamide (ac) combination chemotherapy regimens. sustol is contraindicated in patients with hypersensitivity to granisetron, any of the components of sustol, or to any of the other 5-ht3 receptor antagonists [see warnings and precautions (5.3), description (11)] . risk summary there are no available data on the use of sustol in pregnant women. limited published data on granisetron use during pregnancy are not sufficient to inform a drug-associated risk. in animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits administered granisetron hydrochloride during organogenesis at intravenous doses up to 61 times and 41 times respectively the maximum recommended human dose (mrhd) of sustol 10 mg/week [see data] . the estimated b

United States - English - NLM (National Library of Medicine)

natco pharma limited - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets usp are indicated for the prevention of: nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

New Zealand - English - Medsafe (Medicines Safety Authority)

devatis limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg - solution for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - for the prevention and treatment of nausea and vomiting induced by cytotoxic chemotherapy in adults for the prevention of nausea and vomiting induced by cytotoxic chemotherapy in children

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - granisetron hydrochloride - concentrate for soln for inf - 1 mg/ml - serotonin (5ht3) antagonists

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - granisetron hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - granisetron hydrochloride 1.12mg equivalent to 1.0 mg granisetron base - film coated tablet - 1 mg - active: granisetron hydrochloride 1.12mg equivalent to 1.0 mg granisetron base excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry white 04f58804 purified water   sodium starch glycolate - granisetron is indicated for the prevention of acute and delayed nausea and vomiting associated with cytostatic therapy

Singapore - English - HSA (Health Sciences Authority)

apex pharma marketing pte. ltd. - granisetron hydrochloride 1.12 mg eqv granisetron - injection, solution - 3.0 mg - granisetron hydrochloride 1.12 mg eqv granisetron 1 mg/ml